Dr. Tagawa on the growing role of radiopharmaceuticals in prostate cancer
“What I'm quite hopeful for are PSMA-targeted alpha emitters,” says Scott T. Tagawa, MD, MS, FACP.
In this video, Scott T. Tagawa, MD, MS, FACP, discusses ongoing and upcoming innovation in the radiopharmaceutical space for treatment of prostate cancer, as well as considerations for physicians who are administering these therapies. Tagawa is an associate professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
![Study compares 18F-based PSMA radiotracers to [68Ga]Ga-PSMA-11](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Furologytimes%2F05175eccc72521b2df7a5a848d1602a44b55382e-640x640.webp%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Study compares 18F-based PSMA radiotracers to [68Ga]Ga-PSMA-11")
Bone scans overstage prostate cancer vs PSMA-PET in initial setting
November 21st 2023"Rather than receiving definitive radiation treatment for localized disease, these patients may have received treatment aimed at preventing the further spread of what was incorrectly identified as metastatic disease," says Thomas Hope, MD.
